DASL-HiCaP (ANZUP1801): darolutamide with ADT and radiotherapy in very high-risk localised prostate cancer

NCT04136353

Randomised double-blind placebo-controlled phase 3 trial led by the University of Sydney and ANZUP. Interim analysis presented at ESMO 2026 (24 October 2026): metastasis-free survival HR 0.42 (95% CI 0.27-0.66) at median 3.8 years; overall survival not yet different.